Daihan Pharmaceutical Co.Ltd (KQ:023910) — Market Cap & Net Worth
Market Cap & Net Worth: Daihan Pharmaceutical Co.Ltd (023910)
Daihan Pharmaceutical Co.Ltd (KQ:023910) has a market capitalization of $106.39 Million (₩157.00 Billion) as of June 17, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #19052 globally and #930 in its home market, demonstrating a 5.53% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Daihan Pharmaceutical Co.Ltd's stock price ₩26700.00 by its total outstanding shares 5880000 (5.88 Million). Review how much debt does Daihan Pharmaceutical Co.Ltd carry to assess the company's total debt and financial obligations.
Daihan Pharmaceutical Co.Ltd Market Cap History: 2015 to 2026
Daihan Pharmaceutical Co.Ltd's market capitalization history from 2015 to 2026. Data shows growth from $78.69 Million to $106.39 Million (2.86% CAGR).
Index Memberships
Daihan Pharmaceutical Co.Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$273.60 Billion | 0.04% | #381 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$273.60 Billion | 0.04% | #381 of 1384 |
Weight: Daihan Pharmaceutical Co.Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Daihan Pharmaceutical Co.Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Daihan Pharmaceutical Co.Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Daihan Pharmaceutical Co.Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
Daihan Pharmaceutical Co.Ltd's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $78.69 Million | $124.28 Billion | $13.78 Billion | 0.00x | 0.01x |
| 2016 | $100.41 Million | $139.44 Billion | $17.66 Billion | 0.00x | 0.01x |
| 2017 | $148.75 Million | $144.44 Billion | $24.83 Billion | 0.00x | 0.01x |
| 2018 | $140.39 Million | $158.72 Billion | $28.52 Billion | 0.00x | 0.00x |
| 2019 | $117.37 Million | $168.76 Billion | $28.17 Billion | 0.00x | 0.00x |
| 2020 | $123.76 Million | $166.08 Billion | $17.38 Billion | 0.00x | 0.01x |
| 2021 | $109.32 Million | $171.46 Billion | $22.67 Billion | 0.00x | 0.00x |
| 2022 | $119.10 Million | $184.27 Billion | $24.96 Billion | 0.00x | 0.00x |
| 2023 | $110.58 Million | $195.91 Billion | $28.43 Billion | 0.00x | 0.00x |
| 2024 | $104.40 Million | $204.19 Billion | $33.76 Billion | 0.00x | 0.00x |
Competitor Companies of 023910 by Market Capitalization
Companies near Daihan Pharmaceutical Co.Ltd in the global market cap rankings as of June 17, 2026.
Key companies related to Daihan Pharmaceutical Co.Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Daihan Pharmaceutical Co.Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Daihan Pharmaceutical Co.Ltd's market cap moved from $78.69 Million to $ 106.39 Million, with a yearly change of 2.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩106.39 Million | -8.72% |
| 2025 | ₩116.56 Million | +11.64% |
| 2024 | ₩104.40 Million | -5.59% |
| 2023 | ₩110.58 Million | -7.15% |
| 2022 | ₩119.10 Million | +8.94% |
| 2021 | ₩109.32 Million | -11.67% |
| 2020 | ₩123.76 Million | +5.45% |
| 2019 | ₩117.37 Million | -16.40% |
| 2018 | ₩140.39 Million | -5.61% |
| 2017 | ₩148.75 Million | +48.14% |
| 2016 | ₩100.41 Million | +27.60% |
| 2015 | ₩78.69 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Daihan Pharmaceutical Co.Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $106.39 Million USD |
| MoneyControl | $106.39 Million USD |
| MarketWatch | $106.39 Million USD |
| marketcap.company | $106.39 Million USD |
| Reuters | $106.39 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Daihan Pharmaceutical Co.Ltd
Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions. Daihan Pharmaceutical Co.,Ltd. was founded in 1945 and is headquartered in Seoul, South Korea.